Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May;11(5):e01880.
doi: 10.1002/brb3.1880. Epub 2021 Mar 23.

Selegiline reduces daytime sleepiness in patients with Parkinson's disease

Marco Gallazzi  1 , Marco Mauri  1   2 , Maria Laura Bianchi  3 , Giulio Riboldazzi  4 , Lucia Princiotta Cariddi  1   2 , Federico Carimati  1 , Valentina Rebecchi  1 , Maurizio Versino  1   2
Affiliations

Selegiline reduces daytime sleepiness in patients with Parkinson's disease

Marco Gallazzi et al. Brain Behav. 2021 May.

Abstract

Objectives: Excessive daytime sleepiness (EDS) affects a large percentage of Parkinson's disease (PD) patients, and it is enhanced by dopamine agonist drugs. Currently, there is no treatment of choice for EDS in PD. Our aim was to check the clinical impression that some patients who were given selegiline, a selective inhibitor of monoamine oxidase B, experienced an improvement in their daytime somnolence.

Methods: In the present study, we retrospectively identified 45 Parkinson's disease patients (21 females and 24 males) among those referred to the PD Center in Varese that (a) showed excessive daytime sleepiness, usually developed after the introduction of a dopamine agonist, (b) were given selegiline 10 mg to improve their treatment schedule independently of excessive sleepiness, and (c) in whom the Epworth Sleepiness Scale (ESS) and the Parkinson's Disease Sleep Scale (PDSS) scores were available both before and 3 months after the introduction of selegiline.

Results: We compared the corresponding scores (ESS, PDSS, and UPDRS III) evaluated before and 3 months after the introduction of selegiline by the nonparametric Mann-Whitney U test: The differences showed a statistically significant improvement of somnolence but no change in the UPDRS III scores.

Conclusion: Despite some limitations, our data suggest that selegiline may be a valuable add-on therapy in PD patients to reduce their daytime somnolence.

Keywords: Parkinson’s disease; Selegiline; sleepiness.

PubMed Disclaimer

Conflict of interest statement

Maurizio Versino received a financial support for research activities by Chiesi Pharmaceutical.

References

    1. Abbott, R. D. , Ross, G. W. , White, L. R. , Tanner, C. M. , Masaki, K. H. , Nelson, J. S. , & Petrovitch, H. (2005). Excessive daytime sleepiness and subsequent development of Parkinson disease. Neurology, 65(9), 1442–1446. 10.1212/01.wnl.0000183056.89590.0d - DOI - PubMed
    1. Cereda, E. , Cilia, R. , Canesi, M. , Tesei, S. , Mariani, C. B. , Zecchinelli, A. L. , & Pezzoli, G. (2017). Efficacy of rasagiline and selegiline in Parkinson's disease: A head‐to‐head 3‐year retrospective case‐control study. Journal of Neurology, 264(6), 1254–1263. 10.1007/s00415-017-8523-y - DOI - PMC - PubMed
    1. Devos, D. , Krystkowiak, P. , Clement, F. , Dujardin, K. , Cottencin, O. , Waucquier, N. , & Defebvre, L. (2007). Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 78(5), 470–475. 10.1136/jnnp.2006.100016 - DOI - PMC - PubMed
    1. Du, J. J. , & Chen, S. D. (2017). Current nondopaminergic therapeutic options for motor symptoms of Parkinson's Disease. Chinese Medical Journal (Engl), 130(15), 1856–1866. 10.4103/0366-6999.211555 - DOI - PMC - PubMed
    1. Hogl, B. , Saletu, M. , Brandauer, E. , Glatzl, S. , Frauscher, B. , Seppi, K. , & Poewe, W. (2002). Modafinil for the treatment of daytime sleepiness in Parkinson's disease: A double‐blind, randomized, crossover, placebo‐controlled polygraphic trial. Sleep, 25(8), 905–909. 10.1093/sleep/25.8.62 - DOI - PubMed

LinkOut - more resources